Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab) Clinical Trials

1 actively recruiting trial

Pipeline

Phase 3: 1

Top Sponsors

University Hospital, Montpellier1

Indications

Anti-CD20 Therapy1
Relapsing-remitting Multiple Sclerosis (RRMS)1
Multiple Sclerosis1

Other1 trial

A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.